AstraZeneca Plc (AZN)

45.42
0.80 1.80
NYSE : Health Technology
Prev Close 44.62
Open 45.04
Day Low/High 44.98 / 45.69
52 Wk Low/High 35.30 / 45.28
Volume 6.00M
Avg Volume 2.86M
Exchange NYSE
Shares Outstanding 2.62B
Market Cap 115.59B
EPS 0.80
P/E Ratio 19.92
Div & Yield 1.37 (3.09%)

Latest News

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation For Chronic Lymphocytic Leukemia

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for CALQUENCE ® (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the...

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival In The Phase III FLAURA Trial For 1st-line EGFR-mutated Non-small Cell Lung Cancer

TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival In The Phase III FLAURA Trial For 1st-line EGFR-mutated Non-small Cell Lung Cancer

AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer...

LYNPARZA® (Olaparib) Phase III Profound Trial In HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

LYNPARZA® (Olaparib) Phase III Profound Trial In HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg (two 150 mg tablets) twice daily in men with metastatic castration-resistant...

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data In Unresectable, Stage III Non-small Cell Lung Cancer

IMFINZI® (durvalumab) US Label Updated With Overall Survival Data In Unresectable, Stage III Non-small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the inclusion of overall survival (OS) data from the Phase III PACIFIC trial in an update to the IMFINZI ® (durvalumab) US Prescribing Information for patients with...

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

IMFINZI® (durvalumab) Improves Overall Survival At Interim Analysis In The Phase III CASPIAN Trial In 1st-Line Extensive-Stage Small Cell Lung Cancer

AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

CALQUENCE® (acalabrutinib) Significantly Prolonged The Time Patients Lived Without Disease Progression In Relapsed Or Refractory Chronic Lymphocytic Leukemia

AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing CALQUENCE ® (acalabrutinib) significantly prolonged the time patients...

LOKELMA™ Demonstrated Efficacy In Treating Hyperkalemia In Patients With End-Stage Renal Disease On Hemodialysis

LOKELMA™ Demonstrated Efficacy In Treating Hyperkalemia In Patients With End-Stage Renal Disease On Hemodialysis

AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium cyclosilicate) for the treatment of hyperkalemia in patients with end-stage renal disease (ESRD) on...

FARXIGA Study Showed Reduced Progression Of Kidney Disease Or Renal Death In Patients With Type 2 Diabetes

FARXIGA Study Showed Reduced Progression Of Kidney Disease Or Renal Death In Patients With Type 2 Diabetes

A pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showed that FARXIGA (dapagliflozin) reduced the progression of...

IMFINZI® (Durvalumab) Is The Only Immunotherapy To Demonstrate Overall Survival At Three Years In Unresectable, Stage III Non-Small Cell Lung Cancer

IMFINZI® (Durvalumab) Is The Only Immunotherapy To Demonstrate Overall Survival At Three Years In Unresectable, Stage III Non-Small Cell Lung Cancer

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of IMFINZI ® (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC) during the 2019 American Society of Clinical Oncology (ASCO) Annual...

Bob Harper And AstraZeneca Expand Survivors Have Heart Initiative To Empower And Unite Heart Attack Survivors Nationwide

Bob Harper And AstraZeneca Expand Survivors Have Heart Initiative To Empower And Unite Heart Attack Survivors Nationwide

AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite...

FASENRA® (benralizumab) Reduces Oral Corticosteroid Use And Maintains Long-term Efficacy And Safety Profile In Severe Eosinophilic Asthma

FASENRA® (benralizumab) Reduces Oral Corticosteroid Use And Maintains Long-term Efficacy And Safety Profile In Severe Eosinophilic Asthma

A new integrated analysis of Phase III data for FASENRA ® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and...

AstraZeneca Continues To Redefine Cancer Treatment At The 2019 ASCO Annual Meeting

AstraZeneca Continues To Redefine Cancer Treatment At The 2019 ASCO Annual Meeting

AstraZeneca will present new research across an industry-leading Oncology portfolio, including data for its transformational cancer medicines LYNPARZA ® (olaparib) and IMFINZI ® (durvalumab) at the 2019 American Society of Clinical Oncology (ASCO) Annual...

AstraZeneca Teams Up With PGA Golf Champion Jason Day To Raise Awareness About The Importance Of Biomarker Testing In Lung Cancer

AstraZeneca Teams Up With PGA Golf Champion Jason Day To Raise Awareness About The Importance Of Biomarker Testing In Lung Cancer

AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can...

Change Makers Across The Oncology Community Recognized At 2019 Cancer Community (C2) Awards

Change Makers Across The Oncology Community Recognized At 2019 Cancer Community (C2) Awards

The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards.

Selumetinib Granted US Breakthrough Therapy Designation In Neurofibromatosis Type 1

Selumetinib Granted US Breakthrough Therapy Designation In Neurofibromatosis Type 1

AstraZeneca and Merck & Co., Inc.

Dow Ends Up on 'Constructive' Trade Talks; S&P 500 Logs Best Quarter Since 2009

Dow Ends Up on 'Constructive' Trade Talks; S&P 500 Logs Best Quarter Since 2009

Stocks closes up Friday after U.S. Treasury Secretary Steven Mnuchin says trade talks he held with China were 'constructive.'

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca Slides on $6.9 Billion Cancer Drug Deal with Japan's Daiichi Sankyo

AstraZeneca shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years.

US Futures Gain in Best Quarter Since 2009 as Mnuchin Touts China Trade Progress

US Futures Gain in Best Quarter Since 2009 as Mnuchin Touts China Trade Progress

Global stocks traded higher Friday, lifting U.S. equity markets towards their best opening quarter gain in a decade, as investors crept back into risk markets amid progress in U.S.-China trade talks, modestly higher fixed income yields and the opening trade of the biggest IPO since 2014.

Lyft, Wells Fargo CEO and 'Constructive' Trade Talks - 5 Things You Must Know

Lyft, Wells Fargo CEO and 'Constructive' Trade Talks - 5 Things You Must Know

Stock futures rise after Treasury Secretary Steven Mnuchin says trade talks between the U.S. and China have been 'constructive'; Lyft's IPO is priced at $72 a share, valuing the ride-hailing company at more than $24 billion; Tim Sloan steps down as CEO of Well Fargo.

First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes

First Sub-Analyses From The DECLARE-TIMI 58 Trial Further Support The Cardiovascular Effects Of FARXIGA In Type 2 Diabetes

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin) reduced the relative risk of major adverse cardiovascular events (MACE) by 16% compared to placebo (15.

AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019

AstraZeneca To Present New Cardiovascular Data On FARXIGA In Type 2 Diabetes At ACC 2019

Data evaluating the cardiovascular (CV) effects of FARXIGA ® (dapagliflozin) , including hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the...

TheStreet Quant Rating: B (Buy)